NICE Rejects Novartis’ Xolair In Harbinger Of Cost Reevaluation Process
This article was originally published in The Pink Sheet Daily
Executive Summary
Draft guidance from NICE concludes that Novartis’ asthma drug Xolair, which was previously viewed as cost-effective, is no longer worth the expense based on new independent economic modeling and mortality data. The re-evaluation process is spreading through Europe as governments move to restrain costs, and that may spell trouble for manufacturers.